Wall Street sees Eli Lilly jumping 21%+ in sales and 40%+ in profit by 2026
Wall Street is betting that Eli Lilly can turn its obesity and diabetes franchise into one of the most powerful growth engines in global pharmaceuticals, with analysts projecting revenue to climb more than 21% and adjusted earnings to rise more than 40% by 2026. Those expectations rest on a mix of surging demand for GLP-1…